Embryonic trophectoderm secretomics reveals chemotactic migration and intercellular communication of endometrial and circulating MSCs in embryonic implantation

Alexandra Calle  
Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria

Víctor Toribio-Serrano  
CBMSO: Universidad Autonoma de Madrid Centro de Biologia Molecular Severo Ochoa

María Yáñez-Mó  
CBMSO: Universidad Autonoma de Madrid Centro de Biologia Molecular Severo Ochoa

Miguel Ángel Ramírez  (ramirez@inia.es)  
Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria  
https://orcid.org/0000-0002-5868-2134

Original Article

Keywords: Mesenchymal stromal cells, trophectoderm, epithelial to mesenchymal transition, cell migration, extracellular vesicles.

DOI: https://doi.org/10.21203/rs.3.rs-177701/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Embryonic implantation is a key step in the establishment of pregnancy. In the present work, we have carried out an in-depth proteomic analysis of the secretome (extracellular vesicles and soluble proteins) of two bovine blastocysts embryonic trophectoderm primary cultures (BBT), confirming different epithelial-mesenchymal transition stages in these cells. BBT-secretomes contain early pregnancy-related proteins and angiogenic proteins both as cargo in EVs and the soluble fraction. We have demonstrated the functional transfer of protein-containing secretome between embryonic trophectoderm and maternal MSC in vitro using two BBT primary cultures and 8 endometrial MSC (eMSC) and 5 peripheral blood MSC (pbMSC) lines. We observed that eMSC and pbMSC chemotax to both the soluble fraction and EVs of the BBT secretome. In addition, in a complementary direction, we found that the pattern of expression of implantation proteins in BBT-EVs changes depending on: i) their epithelial-mesenchymal phenotype; ii) as a result of the uptake of eMSC- or pbMSC-EVs previously stimulated or not with embryonic signals (IFN-τ), and iii) because of stimulation with endometrial cytokines present in the uterine fluid in the peri-implantation period.

Introduction

Embryo implantation is a crucial step for pregnancy establishment. In ruminants, noninvasive trophoblast attaches and adheres to the uterine endometrium, followed by the formation of the placenta. It has been demonstrated that during the adhesion of the embryo to the endometrium on day 22, the embryonic trophoblast upregulates the expression of genes characteristic of an epithelial to mesenchymal transition (EMT) [44]. Lee et al demonstrated that cell-cell interaction continues during conceptus implantation into the endometrium and that EMT is the key process for many events that facilitate embryonic development, for which the expansion of epidermal basal compartments, is required [22]. During this period, trophoblast cells must be more flexible, enabling the formation of binucleated and trinucleated cells. It was found that binucleated trophoblast cells exhibit intermediate characteristics between epithelial and mesenchymal phenotypes [31]. Although EMT occurs in different biological processes, the first type of EMT is thus associated with implantation, embryo formation, organ development, and the generation of a variety of cell types with mesenchymal phenotypes [1].

Although this EMT process has been reported in bovine trophoblast cells during embryo implantation [4, 21, 44], its consequences on the cell secretome have not yet been studied. Embryo-maternal communication through secretome, including both extracellular vesicles and soluble proteins, is essential for successful embryonic implantation.

To date, most of the studies that aim to investigate the process of bovine embryo-maternal communication [4, 21, 44] have been performed in vitro with a trophoblast primary culture (CT-1) established by cocultivation with mouse feeder layers [37–39]. Our group isolated and characterized eight primary cultures of bovine blastocyst embryonic trophoblast cells, (BBT, through a novel biopsy and culture system without the need of using coculture with murine cells [32]. The different trophoblastic
primary cultures established showed expression of genes from early trophoblastic markers (CDX2, ELF5), mononucleated cells (IFNT), and binucleated cells (PAG1, PRP1, and CSH2), which varied with time in culture, indicating that these primary cultures are dynamic populations [32].

Recently, our group described for the first time the isolation, immortalization, and characterization of endometrial mesenchymal stem cell lines (eMSC) from different estrous cycle stages, with a clear mesenchymal pattern and immunomodulatory properties. Our study also reported that the migratory capacity of these eMSCs was increased towards an inflammatory niche but was reduced in response to the presence of the bovine implantation cytokine interferon tau-1 (IFN-τ). The combination of both signals (pro-inflammatory and implantation) would ensure the retention of eMSC in the case of pregnancy. Interestingly, in the absence of embryo stimuli, eMSC showed an apparent mesenchymal to epithelial transition stage [9]. Also, we have just reported the successful isolation for the first time in bovine, of peripheral blood MSC (pbMSCs) lines with classical MSC markers, multipotent capacity, and immune-suppression activity. Interestingly, in contrast to MSCs derived from endometrial tissue, some pbMSC lines showed chemotactic activity towards the IFN-τ implantation cytokine as well as towards a raw secretome of BBT. Our results would thus suggest that circulating MSCs are present in the peripheral blood under healthy conditions and can be actively recruited to the implantation niche during pregnancy. Retention of eMSC and recruitment of pbMSC would ensure the necessary immunorepression to prevent embryo rejection by the maternal organism [8].

The main objective of the present work is to carry out an in-depth analysis of the secretome (extracellular vesicles and soluble proteins separately) of two BBT primary cultures that represent two different stages of epithelial-mesenchymal transition of the embryonic trophectoderm, and their effects on chemotactic migration of maternal eMSC and pbMSC. To demonstrate the functional consequences of this secretome-based maternal-embryonic communication, we have analyzed both the uptake of EVs from BBT by maternal MSC as well as the changes in BBT secretome as a result of the uptake of eMSC- or pbMSC-EVs or after treatment with endometrial cytokines present in the uterine fluid in the peri-implantation period.

**Materials And Methods**

**Cells**

Bovine blastocyst embryonic trophectoderm primary cultures (BBT): BBT-9 and BBT-18 primary cultures were established in our laboratory from an embryo biopsy of good quality bovine hatched blastocysts produced in vitro [19].

Endometrial mesenchymal stem cell (eMSC) lines: eMSC-1A, -3A, -3D, -3E, -4B, -4C, -4D and -4H were isolated, established, and immortalized (PA-317 LXSN-16E6E7 cells) in our laboratory from the uterus of heifers at different oestrous cycle stages [6].
Peripheral blood mesenchymal stem cell (pbMSC) lines were isolated and established in our laboratory from male heparinized whole blood. The pbMSC-80, -81, and – 84 cell lines were obtained by previous bone marrow mobilization using granulocyte colony-stimulating factor (G-CSF), and pbMSC-922, -923 without it [8].

**Production and isolation of BBT primary cultures (BBT-9 and BBT-18) secretome (EVs and soluble proteins).**

The proceedings for the isolation and quantification of the secretome produced by BBT-9 and BBT-18 primary cultures were performed as detailed in [8]. FBS was depleted of bovine EVs by ultracentrifugation at 100,000 x g for 16 h (Sorvall AH- 627 rotor, L8–70M ultracentrifuge, Beckman). Conditioned media from BBT cultured with EVs depleted 10% FBS, was collected after 72h of confluent culture, centrifuged at 2.000 x g for 30 min, and concentrated by centrifugation at 2.000 x g for 50 min. using Amicon Ultra-15 Centrifugal Filter Units (Millipore, Billerica MA). EVs production and isolation were carried out following the procedures of Suarez et al with minor modifications [36]. Briefly, the whole supernatant (± 150µl) was loaded onto a 1 mL Sepharose CL-2B (Sigma Aldrich) size exclusion chromatography (SEC) column. Elution was performed by gravity adding PBS, collecting 20 sequential fractions of 100 µl. The presence of EVs in the collected fractions was detected by dot blot and bead-assisted flow cytometry using typical exosome markers (CD9 and CD63); EVs started to be eluted in fraction 3.

**Characterization of BBT primary cultures (BBT-9 and BBT-18) EVs by bead-assisted flow cytometry assay**

The selection of SEC fractions enriched in EVs was performed by bead-based flow cytometry analysis of each fraction using anti-CD63 (CC25 Bio-Rad) and anti-CD9 (VJ1/20) antibodies (Fig. 2). The three fractions with the highest MFI values for these EVs markers (commonly 3rd–6th) were pooled for further EVs downstream analyses. 10µl of each fraction isolated by SEC were incubated with 0.25 µl of aldehyde/sulfate latex beads (ø = 4 µm; 5.5 × 10^6 particles/ml; Invitrogen, Carlsbad, CA) for 15 min at RT. Then, 1 ml of PBS supplemented with 0.1% BSA (PBS-BSA); Thermo Fisher Scientific) was added and the sample was incubated overnight on rotation. Bead-coupled EVs were pelleted by centrifugation at 2,000 x g for 10 minutes, washed with 1 ml of PBS-BSA, and centrifuged again. The pellet was resuspended with 50 µl of PBS-BSA per analysis and stained using murine hybridoma supernatant of anti-CD9 (VJ1/20) and anti-Bovine-CD63 (CC25 Bio-Rad) as primary antibodies and FITC-conjugated secondary antibodies (Thermo Fisher Scientific) [24]. Negative control was obtained by incubating the beads coupled with the EVs sample, in the absence of primary Ab. Washing steps were performed once after primary and twice after secondary Ab labeling with 1ml of PBS-BSA and centrifugation at 2,000 x g for 10 minutes. Data were acquired in a conventional flow cytometer (FACSCanto A, BD Biosciences, San Jose, CA) and analyzed with the FlowJo software (version Tree Star, Ashland, OR). Gating of EVs-decorated 4 µm diameter beads was performed based on FCS/SSC parameters so that unbound EVs or possible antibody aggregates are excluded from the analysis.
The selection of BBT-9 and BBT-18 SEC fractions enriched in soluble proteins was performed by quantification with a Nanodrop spectrophotometer (Thermo Fisher Scientific) at 280 nm absorbance using 2 µl per fraction. The SEC fractions with the highest soluble protein content were selected and pooled.

**BCA protein analysis**

The protein concentration of EVs and soluble protein SEC fractions pooled was assessed following the Pierce® BCA Protein assay kit protocol. Duplicates of the sample’s absorbance at 540 nm were measured in a Tecan GENios Microplate reader.

**Dot blot analysis**

EVs samples were directly dispersed onto a nitrocellulose membrane (Amersham). Membranes were blocked with 10% skimmed milk and incubated with anti-CD9 (VJ1/20) [24] followed by peroxidase-coupled secondary antibodies and detected by chemiluminescence with an ImageQuant LAS500 biomolecular imager (GE LifeSciences).

**Transmission electron microscopy (TEM)**

To assess the size and morphology of EVs using transmission electron microscopy, ionized carbon and collodion-coated copper electron microscopy grids were floated on a sample drop, washed, and stained with 2% uranyl acetate (in double-distilled water) for 1 min, and visualized in a JEM-1010 (JEOL, Tokyo, Japan) transmission electron microscope. A quantitative evaluation of the BBBT-18 and BBBT-9 trophectoderm primary cultures in terms of particle diameters were determined by the computer-assisted software TEM ExosomeAnalyzer [20].

**BBT-EVs binding to MSC**

To assess the BBT-EVs and MSCs interaction, a 2D chemotaxis assay was developed using PKH26-labeled BBT-9 and BBT-18 according to the manufacturer’s instructions. Briefly, the labeling of cells with PKH26 (Red Fluorescent Cell Linker Kits MINI26; Sigma-Aldrich Co., St Louis, MO, USA) was performed for 5 minutes at RT in the dark and blocked with FBS. The unincorporated stains were removed by BBT centrifugation at 400 g for 10 minutes at RT using Heraeus Biofuge Primo R Centrifuge. The BBTs were washed with PBS and subjected to additional centrifugation. The pellet was resuspended, and labeled cells were plated in a 100-mm² tissue culture dish (JetBiofil, Guangzhou, China) and incubated in an atmosphere of humidified air and 5% CO₂ at 37°C for 72 h. Culture media was supplemented with 10% of EVs-depleted FBS. EVs were then isolated by SEC from BBT conditioned media. A cell migration analysis by agarose spot assay with labeled EVs from BBT was carried out following the procedures of the 2D chemotaxis assay described below in materials and methods. A control with BBT-EVs from unlabeled BBT was done. After O/N incubation, MSCs were visualized in fluorescence microscopy.

**Identification and quantification of secretome (EVs and soluble fraction) derived proteins of BBT cells by LC-MS/MS.**
To achieve the most accurate characterization of soluble protein fractions for the HPLC technique, we did not add FBS to BBT-9 and BBT-18 culture media to produce conditioned media without FBS. This allowed us to avoid possible confusion between bovine proteins contained naturally in the FBS and proteins secreted by BBT cells. In the case of EVs protein samples and the control group from culture media, FBS was EVs depleted and analyzed by HPLC.

**Sample preparation for LC-MS/MS**

After denaturation of protein with 8 M urea in 50 mM ammonium bicarbonate pH 8.8, samples were reduced and alkylated, briefly: disulfide bonds from cysteiny1 residues were reduced with 10 mM DTT for 1 h at 37 °C, and then thiol groups were alkylated with 10 mM iodoacetamide for 30 min at room temperature in darkness. Samples were diluted to reduce urea concentration below 1.4 M and digested using sequencing grade trypsin (Promega, Madison, WI) overnight at 37º C using a 1:20 (w/w) enzyme:protein ratio. Digestion was stopped by the addition of 1% TFA. EVs samples whole supernatants were dried down and then desalted onto Pierce Peptide Desalting Spin Columns (Thermo), and secretome samples in OASIS C18 columns (Waters), until the mass spectrometric analysis. Protein Identification by reverse phase-liquid chromatography-mass spectrometry analysis (RP-LC-MS / MS), Data processing and Protein quantification by LC-MS / M iTRAQ labeling and high pH fractionation, detailed in Sup. Method 1.

**In vitro model of chemotactic migration of MSC by BBT secretome**

The cell migration measurement by agarose spot assay was carried out following the procedures of Calle et al [7, 9]. A 0.5% agarose solution in PBS was heated on a water bath until boiling to facilitate complete dissolution. When the temperature cooled down to 40°C, 90 µl of the agarose solution was pipetted into a 1.5-ml Eppendorf tube containing 10 µl of PBS, EVs (0.2 µg/µl), or soluble proteins (0.2 µg/µl)) from BBT-9- or –BBT-18. 5-microliter spots of agarose-containing PBS, EVs, or soluble proteins were pipetted onto 12-well plates (JetBiofil, Guangzhou, China), and allowed to cool down for 15 min at 4°C. At this point, 2.5x10^5 cells were plated carefully onto spot-containing wells in the presence of culture media. After a period of resting within the cells attached to the plate in the incubator, imaging was performed in temperature, humidity, and CO₂ controlled chamber for 20h by FRET microscope (Zeiss Axiovert200) coupled to a monochrome digital camera (Hamamatsu C9100-02). Pictures were taken each 10 min and processed using Metamorph 7.10.1.16 software. We measured different parameters to achieve a deep description of cell migration, such as Maximum Euclidean distance (MED) to the stimuli. This parameter represents the maximum length of the straight traveled distance by cells (µm) from the edge of the spot to the center, which is the reference point for the stimuli position. Moreover, it was also tracked the random choice of cells present at the edge of the drop at the beginning of the experiment to measure the mean speed (µm/min), the accumulated distance, the center of mass (COM) that is the average position of starting and end cell points of all tracked cells, and finally, the density of cell endpoints represented by Rose diagrams showing the most common direction taken for motile cells. The MED from the border of the spot was measured for each drop using Image J free software. The rest of the evaluated parameters were measured using the Chemotaxis and Migration Tool (free software IBIDI) combined with the manual
tracking plugin of Image J. We have always tracked the cells in the same drop quadrant to avoid differences in the reference point. All experiments were replicated at least 3 times.

**Analysis of changes in BBT EVs profile after uterine cytokines stimuli or communication with MSC EVs**

To assess the changes in implantation protein profiles in BBT-EVs as a result of BBT-MSC *in vitro* communication, pre-confluent 100-mm² tissue culture dishes of BBT-9 and BBT-18 were cultured for 48h in media supplemented with MSC-EVs isolated by SEC from stimulated or unstimulated MSC. Confluent 100-mm² tissue culture dishes of eMSC or pbMSC were cultured for 48 h with or without IFN-τ stimulation (MBS1131960, Mybiosource) (1000 ng/ml). Then, EVs from the different eMSC or pbMSC lines were pooled separately. In addition, to assess uterine cytokines effect on BBT-EVs, pre-confluent 100-mm² tissue culture dishes of BBT-9 and BBT-18 were cultured in media supplemented with Activin A (PHC9564, Thermo Fisher Scientific) (100 ng/ml), Activin A and *FSTL1* (10924H08H50, Thermo Fisher Scientific) (100 and 50 ng/ml respectively) or without cytokines during 48h. The experimental design is shown in Fig. 1. Bead- assisted flow cytometry was performed to BBT-EVs obtained following the procedures besides described to analyze the implantation marker expression of *MMP2* (MA1-772, Thermo Fisher Scientific); *HSPH1* (PA5-77793, Thermo Fisher Scientific); *TDGF1* (NB100-1597, Novus Biologicals) and *PEG3* (TA343590, Acris-antibodies).

**Statistical analysis**

All experiments were repeated with at least three independent biological replicates. One-way ANOVA with Tukey multiple comparison tests and Two-way ANOVA with Sidak multiple comparison tests. All results are expressed as mean ± SEM or as median (range). All the analyses and relative graphs were made in Prism 9.0 (GraphPad Software Inc., La Jolla, CA, USA). For the statistical analysis of rose diagrams, we have used the Rayleigh test. This is a statistical test for the uniformity of a circular distribution of cell endpoints included in Chemotaxis and migration tool software.

**Results**

**The proteomic profiles of BBT-9 and BBT-18 secretome (EVs and soluble proteins) are compatible with different EMT stages.**

To analyze the components of the BBT secretome, conditioned media from cell cultures of BBT-9 and BBT-18 were fractionated by SEC. Collected fractions were quantified with a Nanodrop spectrophotometer (Fig. 2a), characterized by bead-assisted flow cytometry using antibodies against classical EVs-markers CD63 and CD9 [36], showing both strong expressions in EVs-fractions, and by Dot Blot against CD9 (Fig. 2b). Transmission electron microscopy confirmed the presence of EVs in the BBT-9 and −18 secretome (Fig. 2c), with a similar diameter (133, 150 nm), perimeter (466, 524 nm), and roundness (0.8) (Fig. 2d).

We then analyzed by mass spectrometry the secretome of these early implantation stage embryonic BBTs, with special attention to changes in the secretion profile of proteins related to embryonic
implantation at early pregnancy, angiogenic proteins, as well as changes resulting from an epithelial to mesenchymal transition (EMT).

We performed a comparative protein analysis between the EVs fractions from BBT-9 and BBT-18 conditioned media and the same fractions from the non-conditioned culture medium (control). Although in all cases FBS in culture media had been depleted from EVs by long-term ultracentrifugation, we could still detect in the proteomic analysis some remnant EVs components in non-conditioned media. Since our cells are from bovine origin, these proteins cannot be filtered from the data. Yet, a total of 1231 proteins, out of 1577 were specific from BBT-conditioned media, and only 49 proteins were exclusively detected in the non-conditioned medium (Fig. 3a). A total of 1090 protein groups were detected in EVs samples, from which 711 were common and 184 and 195 proteins were differentially expressed in BBT-9 and BBT-18 respectively (Fig. 3a).

The mass spectrometry analysis performed on the soluble protein fractions from SEC detected 1285 protein groups, from which 547 were common to both BBT samples and 454 and 284 were differentially expressed in BBT-9 and BBT-18 respectively (Fig. 3b), considering differences bigger than 2-fold in all comparative analyses.

These proteomic data were subjected to a bioinformatic analysis using the UniProt database. GO (Gene Ontology) analyzes were performed using the PANTHER database (Supplementary Fig. 1–4). Classification of the identified proteins either in the soluble fraction or EVs-cargo of BBT-9 and BBT-18, following biological processes, molecular function, and protein class was performed and differences were observed between BBT-9 and BBT-18 in both the soluble fraction and EVs-cargo proteins in protein families related to structural molecule activity, biological adhesion, or reproduction (Supplementary Fig. 1–4).

Interestingly, more detailed scrutiny of the BBT-9 secretome revealed the presence of the EMT markers Transforming growth factor-beta (TGFB), Collagen alpha-2(I) chain (COL1A2), and Vimentin (VIM) in both the soluble and the EVs fraction, while fibroblast growth factor receptor (FGFR1) and 72 kDa type IV collagenase (MMP2) were exclusively present in the soluble fraction (Fig. 3c). The epithelial marker Cadherin-1 (CDH1) and the pregnancy epithelial marker mucin-1 (MUC1) were exclusively expressed in the BBT-18 soluble fraction and EVs respectively (Fig. 4B and Table 1).
Table 1
Top early pregnancy-related proteins differentially abundant between BBT18- and BBT9-soluble proteins detected by iTRAQ-LC-MS/MS analysis.

| Description                                | Mean fold change BBT18:BBT9 | Gene name | Accession number | Reproductive event                  |
|--------------------------------------------|----------------------------|-----------|------------------|-------------------------------------|
| Pregnancy-associated glycoprotein 2        | 53.54                      | PAG2      | Q28057           | co. marker peri-elongation          |
| Secreted seminal-vesicle Ly-6 protein 1    | 16.24                      | SSLP1     | P83107           | co. marker peri-gastrulation        |
| 14-3-3 protein sigma                       | 15.76                      | SFN       | Q0VC36           | Trophoblast marker                 |
| Interferon tau-1                           | 13.13                      | IFNT1     | P15696           | Implantation/Co. secretion          |
| Trophoblast Kunitz domain protein 1        | 10.96                      | TKDP      | Q28201           | Trophoblast marker/Co marker peri-elongation |
| Keratin type II cytoskeletal 8             | 9.67                       | KRT8      | F1MU12           | Trophoblast marker                 |
| Ezrin                                      | 7.52                       | EZR       | P31976           | Implantation                       |
| Galectin                                   | 5.25                       | LGALS3    | A6QLZ0           | co. marker peri-gastrulation        |
| Interferon tau-3                           | 4.99                       | IFNT3     | P56831           | Implantation/Co. secretion          |
| Furin                                      | 3.53                       | FURIN     | Q28193           | co. marker peri-gastrulation        |
| CD44 antigen                               | 2.91                       | CD44      | Q29423           | co. marker peri-gastrulation        |
| Retinoic acid receptor responder 1         | 2.32                       | RARRES2   | Q29RS5           | Trophoblast marker                 |
| Macrophage-capping protein                 | 2.24                       | CAPG, ACFP, MCP | Q865V6 | co. marker peri-elongation          |
| Vimentin                                   | -10                        | VIM       | P48616           | co. marker peri-gastrulation        |
| 72 kDa type IV collagenase                 | -10                        | MMP2      | F1MKH8           | Implantation/Co. secretion          |
| Follistatin-related protein 1              | -5.3                       | FSTL1     | Q58D84           | Implantation                       |
| Fibronectin                                | -5                         | FN1       | G5E5A9           | co. marker peri-gastrulation        |
| Description                                         | Mean fold change BBT18:BBT9 | Gene name | Accession number | Reproductive event                              |
|-----------------------------------------------------|----------------------------|-----------|------------------|------------------------------------------------|
| Heat shock cognate 71 kDa protein                   | -3                         | HSPA8     | P19120           | Trophoblast marker/Co marker peri-elongation    |
| 10 kDa heat shock protein mitochondrial             | -2.7                       | HSPE1     | A0A3Q1N8Q5       | co. marker peri-elongation                      |
| Plastin-3                                           | -2.3                       | PLS1      | A6H742           | Trophoblast marker                              |
| Fibroblast growth factor receptor                   | -1.8                       | FGFR1     | F1MQI5           | co. marker peri-elongation                      |

**The BBT-secretomes contain early pregnancy-related proteins and angiogenic proteins both in the soluble fraction and EVs-cargo**

The proteomic analysis also identified 62 early pregnancy-related proteins (EPRP), 41 in EVs fractions (Tables 2, 3), and 21 soluble proteins (Table 1). BBT-18 and BBT-9 overexpressed 13 and 8 EPRP in the soluble fraction (Fig. 4a) and 12 and 7 EPRP in EVs (Fig. 4b), respectively. From the set of 41 EPRP proteins in EVs, we identified a group of 18 proteins corresponding to a day 16 conceptus, commonly expressed in BBT-18 and BBT-9 (Table 3).
Table 2
Top early pregnancy-related proteins differentially abundant between BBT18- and BBT9-EV-cargo detected by iTRAQ-LC-MS/MS analysis.

| EV-cargo proteins                                      | Mean fold change BBT18:BBT9 | Gene name | Accession number | Reproductive event                  |
|--------------------------------------------------------|-------------------------------|-----------|------------------|-------------------------------------|
| Mucin-1                                                | 8.47                          | MUC1      | Q8WML4           | Epithelial. Implantation             |
| Ezrin                                                  | 7.69                          | EZR       | P31976           | Implantation                         |
| Macrophage-capping protein                             | 4.27                          | CAPG      | Q865V6           | Co. secretion d16 pregnant cow.      |
| CD9 antigen                                            | 4.27                          | CD9       | P30932           | Implantation (in vitro)              |
| 14-3-3 protein sigma                                   | 4.17                          | SFN       | Q0VC36           | Trophoblast marker                   |
| Moesin                                                 | 4.11                          | MSN       | Q2HJ49           | Co. secretion d16 pregnant cow.      |
| Thioredoxin                                            | 3.94                          | TXN       | O97680           | Co. secretion d16 pregnant cow.      |
| Cystatin-B                                             | 3.73                          | CSTB      | A0A140T831       | Co. secretion d16 pregnant cow.      |
| Keratin type II cytoskeletal 8                         | 3.59                          | KRT8      | P05786           | Implantation                         |
| PGM2 protein (Fragment)                                | 2.7                           | PGM2      | A6QQ11           | Co. secretion d16 pregnant cow.      |
| Actin-related protein 2/3 complex subunit 5-like protein| 2.19                          | ARPC5L    | Q5E963           | Co. secretion d16 pregnancy cow.     |
| Heat shock protein 105 kDa                             | 2.1                           | HSPH1     | Q0IIM3           | Co. secretion d16 pregnancy cow.     |
| Galectin                                               | -6.12                         | LGALS3    | A6QLZ0           | Co. marker peri-elongation           |
| Embryo-specific fibronectin 1 transcript variant       | -5.56                         | FN1       | B8Y9S9           | Co. secretion peri-gastrulation      |
| Plastin-1                                              | -5.10                         | PLS       | A6H74            | Co. secretion d16 pregnant cow.      |
| EV-cargo proteins                                      | Mean fold change BBT18:BBT9 | Gene name | Accession number | Reproductive event               |
|--------------------------------------------------------|----------------------------|-----------|------------------|----------------------------------|
| Vimentin                                               | -5.00                      | VIM       | P48616           | Co. secretion and EMT            |
| Embryo-specific fibronectin 1 transcript variant       | -5.56                      | FN1       | B8Y9S9           | Co. secretion peri-gastrulation  |
| Alpha-fetoprotein                                      | -2.86                      | AFP       | Q3SZ57           | Co. secretion peri-gastrulation  |
| VCAM1 protein                                          | -2.04                      | VCAM1     | A7MBB0           | Implantation                     |
Table 3
Early pregnancy-related proteins coexpressed in BBT18- and BBT9-EV-cargo detected by iTRAQ-LC-MS/MS analysis. *Pregnancy related proteins reported on in vivo day 16 conceptus in literature (Forde et al., 2015, #2233).

| Secreted proteins                                           | Mean fold change BBT18:BBT9 (≤1.5) | Gene name   | Accession number |
|-------------------------------------------------------------|------------------------------------|-------------|------------------|
| Plastin-3                                                  | 1.8                                | PLS3*       | A7E3Q8           |
| Heat shock cognate 71 kDa protein                          | 1.5                                | HSPA8*      | P19120           |
| CD44 antigen                                                | -1.36                              | CD44*       | Q29423           |
| Nuclear transport factor                                    | -1.28                              | NUTF2*      | Q32KP9           |
| Protein disulfide-isomerase                                 | 1.15                               | P4HB*       | P05307           |
| Collagen type V alpha 1 chain                               | -1.29                              | COL5A1*     | G3MZI7           |
| Alpha-actinin-1 OS = Bos taurus                             | 1.87                               | ACTN1*      | Q3B7N2           |
| Creatine kinase U-type mitochondrial                       | 1.53                               | CKMT1*      | Q9TTK8           |
| Elongation factor 2 OS = Bos taurus                         | 1.63                               | EEF2*       | Q3SYU2           |
| Rab GDP dissociation inhibitor alpha                        | -1.42                              | GDI1*       | P21856           |
| Phosphatidylinositol-glycan-specific phospholipase          | -1.58                              | GPLD1*      | P80109           |
| Heterogeneous nuclear ribonucleoprotein A1                 | 1.23                               | HNRNPA1*    | P09867|         |
| Heterogeneous nuclear ribonucleoproteins A2/B1             | -1.21                              | HNRNPA2B1*  | Q2HJ60           |
| Heterogeneous nuclear ribonucleoprotein F                  | -1.03                              | HNRNPF*     | Q5E9J1           |
| Proteasome subunit alpha type-4                            | -1.04                              | PSMA4*      | Q3ZCK9           |
| 26S proteasome regulatory subunit 6B                        | -1.63                              | PSMC4*      | Q3T030           |
| Serpin A3-2                                                 | -1.36                              | SERPINA3*   | A2I7M9           |
| 14-3-3 protein gamma                                        | -1.02                              | YWHAG*      | A7Z057           |
| Integrin alpha-V                                           |                                    | ITGAV       | P80746           |
| Integrin beta-1                                             |                                    | ITGB1       | P53712           |
| Integrin alpha-5                                            |                                    | ITGA5       | F1MK44           |
| Integrin beta                                               |                                    | ITGB3       | F1MTN1           |
Interestingly, we could also detect a series of proteins related to angiogenic pathways (Table 4), five of them found in both BBT-9 and BBT-18 secretomes, four overexpressed in BBT-9, and two overexpressed in BBT-18.

**Table 4**
Angiogenic proteins expressed in soluble fraction and EV-cargo from BBT-secretome, detected by iTRAQ-LC-MS/MS analysis.

| Angiogenesis pathway                              | Mean fold change | Gene        | Accession number | Secretome                        |
|--------------------------------------------------|------------------|-------------|------------------|----------------------------------|
| Catenin Beta-1                                   | co-expressed     | CTNNB1      | Q0VCX4           | EV and soluble proteins          |
| Mitogen-activated protein kinase 1               | co-expressed     | MAPK1       | P46196           | EV and soluble proteins          |
| Serine/threonine-protein kinase PAK-1            | co-expressed     | PAK 1       | Q08E52           | soluble proteins                 |
| Transformin protein RHOA                         | co-expressed     | RHOA        | P61585           | EV                               |
| MAP2K1                                           | co-expressed     | MAP2K1      | Q0VD16           | EV                               |
| Serine/threonine-protein kinase A-RAF            | 2,17             | ARAF        | A0A452DI16       | Soluble proteins BBT18           |
| Heat Shock protein Beta-1                       | 2,29             | HSPB1       | Q3T149           | EV BBT18                         |
| Fibroblast growth factor receptor 1             | -1,9             | FGFR1       | A0A3Q1LUE0       | Soluble proteins BBT9            |
| RHO GTPase-activating protein 1                  | -4               | ARHGAP1     | F6RWK1           | Soluble proteins BBT9            |
| RHO-related GTP-binding protein RHOC             | -3,57            | RHOC        | Q1RMJ6           | Soluble proteins BBT9            |
| Vascular cell-adhesion molecule                  | -2,04            | VCAM1       | Q9GKR2           | EV-BBT9                          |

**Endometrial and blood MSCs show chemotactic migration to the secretome of the embryonic trophectoderm cells**

We aimed to build an *in vitro* model of cell-to-cell communication through EVs and soluble proteins. To demonstrate the functional transfer between embryonic trophectoderm and maternal MSC of protein-containing secretome, we first confirmed that EVs isolated from conditioned media of BBT cells previously labeled with PKH26 were successfully uptaken by maternal eMSC and pbMSC during a chemotaxis experiment in an agarose spot assay following the procedures of Calle et al [7, 9] as described in materials and methods (Supplementary Fig. 5).
To test the functionality of this maternal-embryonic communication system we analyzed the chemotactic effect of BBT secretome on the migration of maternal eMSC and pbMSC using an agarose spot assay. All MSC lines increased their migration towards BBT-9- or BBT-18-soluble proteins or EVs in terms of maximum Euclidean distance (MED) except pbMSC towards BBT-18-EVs (Fig. 5a, b and supplementary video 1). It should be taken into account that without strong chemotactic stimuli, the physical constraints imposed by the agarose spot impedes the migration of MSCs towards the center of the drop so that in a rose diagram (Fig. 5a), it appears as if MSC were repelled by the drop and migrated to the opposite direction, so that and the Center Of Mass of the population appears ≥ 74 µm outside the edge of the drop (Fig. 5c and d). In contrast, when soluble proteins or EVs were used as stimuli, MSC lines showed their COM near the edge or inside the agarose drop (< 65 µm). pbMSC were the most migratory lines when they were stimulated with soluble protein from both BBT-9 and BBT-18, while they were also the fastest without stimulation or with protein stimulation from BBT-9, EVs-cargo, or soluble protein (Fig. 5e).

**Embryonic trophectoderm EVs change their implantation protein profile after uptake of maternal MSC-EVs**

Since maternal/embryo communication is a bidirectional phenomenon, we next analyzed the changes in the secretome of BBT as a result of the uptake of either eMSC- or pbMSC-EVs or after treatment with the endometrial cytokines Activin A and follistatin (*FLST1*). Activin A and *FLST1* present in the uterine fluid in the peri-implantation period. Activin A induces EMT in human and bovine trophoblast cells and *FLST1* is an inhibitor of Activin A. To analyze the interaction between activin A and *FLST1* in bovine trophoblasts with epithelial or mesenchymal phenotype, BBT-9 or BBT-18 cells were treated with Activin A or Activin A + *FLST1*. MSC-EVs were isolated by SEC from conditioned media of eMSC or pbMSC stimulated or not during 48 h with IFN-τ. Then, EVs from the different lines and conditions were pooled separately. BBT-9 and BBT-18 were then cultured for 48h in media supplemented with the different EVs or in the presence of Activin A, Activin A, and *FSTL1* or without cytokines (Fig. 1). EVs were then isolated from the conditioned media of BBT cultures. The amount of EVs secreted by trophectoderm cells was analyzed by quantifying the CD9 signal in a dot blot using ImageJ software (Fig. 6a). Activin A or BBT-18-EVs treatments showed CD9 Overexpression ≥ 2-fold.

We then focused on a serie of proteins related to the process of invasive growth and involved in the regulation of embryo implantation and analyzed them on BBT-derived EVs by bead assisted flow cytometry. We observed constitutive secretion in both BBT-9- and BBT-18-EVs of *PEG3* implantation protein as well as high recovery of *HSPH1* in BBT-18-EVs (Fig. 6b and c). When the BBTs primary cultures were stimulated with Activin A or with the combination of Activin A and *FLST1*, their EVs cargo now contained the full repertoire of implantation proteins assessed: *MMP2, TDGF1, HSPH1*, and *PEG3*.

Regarding stimulation with EVs from MSC, bigger changes were observed in BBT-9 when EVs were derived from eMSC than from pbMSC. Thus, eMSC-EVs stimulation induced the incorporation of *MMP2* and *TDGF1* in BBT-EVs cargo. In contrast, these changes were smaller when the trophectoderm cells were stimulated with EVs derived from eMSC that had been previously stimulated with IFN-τ. *HSPH1* recovery in trophectoderm EVs showed very different behavior in BBT-9 and BBT-18 primary cultures. BBT-18
showed an exhibiting remarkable *HSPH1* expression, which was further increased by Activin stimulation, all other stimuli impaired its accumulation in EVs, including the combination of Activin A and follistatin and all the MSC-derived EVs treatments.

**Discussion**

Recently, our group characterized for the first time endometrial mesenchymal stem cell lines (eMSC) [9] as well as peripheral blood MSC (pbMSCs) lines [8]. While eMSC showed a reduced migratory capacity in response to the implantation cytokine IFN-τ [9], pbMSC showed chemotactic behavior to both inflammation (TNFα, IL1β), embryo implantation stimuli (IFN-τ) or BBT-secreome, suggesting that the embryo secretome plays a role in ensuring the retention of eMSC and the active recruitment of MSCs from bone marrow during early pregnancy to repress the immune response to prevent the embryo rejection by the maternal organism [8].

During bovine pregnancy, trophoblast adhesion and placental formation has been reported to require a gradual loss of epithelial characteristics but without the acquisition of full mesenchymal characteristics [44]. This partial EMT concurs with gene expression changes associated with EMT in the bovine trophectoderm following conceptus attachment to the luminal epithelium [44]. After conceptus implantation the trophectoderm loses the adherents junction molecule CDH1, and gained the expression of mesenchymal markers, such as VIM and CDH2, maintaining however, the expression of the epithelial marker cytokeratin. Trophectoderm EMT was thereafter shown to be regulated by the endometrium via activin A and FLST1 on days 20–22 [21]. Trophoblast binucleate cells in the bovine placentome showed a cytoplasmic distribution of CH1 and b-catenin translocation into the nucleus [28], suggesting a role for CDH1–b-catenin axis in trophoblast differentiation. On day 22 trophoblasts CDH2 is highly expressed, so that an increment in CDH1 degradation could also be involved in the further reduction of its expression. Hence, the loss of CDH1 as the conceptus attaches to luminal epithelium, may play a crucial role in gene expression transition required for the successful progression from implantation to placentation.

Regarding our BBT primary cultures, we observed that the expression of CDH1 was overrepresented in BBT-18 soluble fraction but not in BBT-9, while BBT-9-secretome is expressing VIM while maintaining cytokeratin expression. These parameters would reflect the two above mentioned phenotypes; epithelial and mesenchymal, respectively. CDH2 was expressed *in vitro* when trophectoderm cells were co-cultured with endometrial epithelial cells [18], but has not been reported in monocultures of trophectoderm cell lines possibly explaining the lack of detection of CDH2 in the BBT-secretome.

EMT induction is regulated at the molecular level by a variety of growth factor signals, in particular transforming growth factor β (*TGF-β*), hepatocyte growth factor (*HGF*), epidermal growth factor (*EGF*), fibroblast growth factor (*FGF*), Wnt proteins, and IL-6 [35]. *TGF-β* is a multifunctional cytokine that is considered the main inducer of EMT. The *TGF-β* signaling pathway plays an important role in regulating cell proliferation, differentiation, invasion, migration, apoptosis, and microenvironmental modification, and stimulates pathophysiological EMT and metastasis [29]. *TGF-β* and *FGFR1* proteins were found to be overrepresented in BBT-9-secretome, suggesting that these proteins could be responsible for the
regulation of EMT in the bovine trophectoderm. In addition, it has been reported that TGF-β is a soluble factor produced by MSCs, which mediates the suppression of T-cell proliferation [13]. Therefore, the BBT-9, thanks to its mesenchymal phenotype, could play an immunomodulatory role via EVs signaling, aimed at guaranteeing the survival of the embryo. Our group has also reported the immunomodulatory capacity of eMSC and pbMSC by inhibiting the proliferation of human T lymphocytes [8, 9].

During EMT, FGF increases the expression of vimentin and induces the activity of MMP2, increasing cell mobility. FGF also causes changes in the actin cytoskeleton allowing anchorage-independent growth [33]. Vimentin and MMP2 are overrepresented in BBT-9-EVs and BBT-9-soluble fractions respectively. Although bovine trophoblasts do not penetrate the endometrium, upregulation of MMP2 metalloproteinase suggests that it could play a role in the non-invasive trophectoderm. FGF1, the ligand for FGFR1, overrepresented in BBT-9-soluble fraction, is also known to upregulate MMP13, resulting in EMT induction [6].

Other characteristic EMT markers such as the transcription factors, SNAI2, ZEB1, ZEB2, TWIST1, TWIST2, and KLF8S were not found in EVs or soluble proteins from BBT-secretome as we could expect since they are nuclear proteins. Likewise, we were also unable to detect pluripotency markers (OCT4/POU5F1, SOX, NANOG) or characteristic markers of trophectoderm (ELF5, EOMES, GATA5) in EVs or soluble proteins from BBT-cargo, although some of the mentioned markers could be detected by RT-PCR in our BBTs [32].

After EMT, a micro-angiogenesis process related to the uterine vascularization is necessary for adequate implantation [16] and placenta formation. We were able to detect eleven proteins involved in angiogenesis pathways in the BBT secretome, from which six participate in the vascular endothelial growth factor (VEGF) pathway. The VEGF signaling pathway is essential for all stages and processes involved in vascular development (vasculogenesis, angiogenesis, and lymphangiogenesis). VEGF is the main factor that regulates angiogenesis in bovine pregnancy. Interestingly, BBT-9 secretome showed an overrepresentation of several angiogenic related factors: Fibroblast growth factor receptor 1 (FGFR1), RHO GTPase-activating protein 1 (ARHGAP1), RHO-related GTP-binding protein (RHOC), and Vascular cell-adhesion molecule (VCAM1). However, in BBT-18 secretome only the Serine/threonine-protein kinase A-RAF (ARAF) and Heat Shock Protein Beta-1 (HSPB1) from this pathway, were found to be overrepresented.

In sum, both the overexpression of EMT markers and the higher detection of angiogenic factors in the BBT-9 protein profile would support the notion that BBT-9 is exhibiting a more advanced developmental stage near to an EMT stage. However, we could not detect in the secretome of BBT the typical bovine pregnancy angiogenic related markers such as VEGF family proteins or its receptor, Angiopoietin (ANGPT)-2/ANGPT-1 [16, 17] due likely to an early developmental stage.

In the bovine species, the expression of integrins (ITGs) has been characterized at the uteroplacental interface during the periods of trophectoderm attachment and placentation [30]. ITGaV (overrepresented in BBT-9-EVs cargo), in combination with the b5 subunit is known to bind to Osteopontin (SPP1) [10]. ITGB1 is also overexpressed in BBT-9-EVs cargo. It can form heterodimers with the α4 chain, also known
as very late antigen-4 (VLA4) often detected in mesenchymal stem cells [3], and α8 subunit resulting in alternative receptors for osteopontin SPP1 [34]. Yamakosi et al observed that the subunits of SPP1-binding ITGs are upregulated during the embryo attachment process and indicate their possible involvement in the trophoblast adhesion to the endometrial epithelium in cows [44]. Moreover, ITG on EVs was reported to dictate organ-specific uptake of EVs to initiate pre-metastatic niche formation in a tumor scenario [44]. Analogously, integrin expression profiles of trophoderm-secreted exosomes could be relevant to direct maternal MSCs to the implantation niche and could be used as prognostic factors to predict good maternal immunoregulation to avoid embryo rejection.

As we have described previously, a correct balance that coordinates active immunity and tolerance during the contact between mother and conceptus is critical. Moreover, it is known that MSCs from the placenta or decidua are involved in the induction of this maternal immune tolerance [23, 43]. In mice, MSCs from bone marrow are involved in the reduction of the embryo resorption rate by regulating the function and phenotype of macrophages and T cells at the maternal-fetal interface [26]. ITG α4β1 major counter ligand, vascular cell adhesion molecule-1 (VCAM-1), plays an important role in leukocyte recruitment during an immune response [5]. Bai et al reported that uterine VCAM-1 expression was minimal in day 17 cyclic and pregnant animals, but increased between days 20 and 22 of pregnancy [3]. The authors also reported that VCAM-1 expression in CT-1 cells (a trophoblast primary culture cultured onto STO mouse feeder cells [44] was up-regulated with the use of uterine flushings. VCAM-1 is found to be overrepresented in BBT-9-EVs cargo. Galectin 3 (LGALS3), also play central roles in immune system regulation, shaping both innate and adaptive responses in physiological and pathological processes [25]. Galectin 3, which is overrepresented in BBT-9-EVs cargo, is first expressed in the trophoderm cells of the implanting embryo and has been implicated in the process of implantation [12].

We have demonstrated that both eMSC and pbMSCs are capable to migrate in response to BBT chemotactic stimuli reinforcing the idea of their participation at the pregnancy establishment. Considering that BBT-9 shows developmental features nearer to EMT than BBT-18, it would suggest that it represents a more advanced developmental stage, closer to embryo implantation than BBT-18. Therefore, our chemotactic data would support that epithelial embryonic trophoderm (BBT-18) stimulates chemotactic migration of maternal MSCs from the endometrium through soluble and EVs mediators, while it attracts peripheral MSC only through soluble mediators. In contrast, when the embryonic trophoderm already presents mesenchymal characteristics (BBT-9), it stimulates the migration of endometrial or stimulates peripheral maternal MSCs through both soluble and EVs-cargo proteins, traveling long distances and at high speed. Therefore, at late implantation stages (BBT-9) secretome-dependent signaling could provoke a highly intensified cell-effect in MSCs to ensure embryo implantation in that critical point of pregnancy.

We next analyzed the changes in the secretome of embryonic trophoderm as a result of the uptake of maternal MSC-EVs or treatment with endometrial cytokines present in the uterine fluid in the peri-implantation period. Activin A is a known member of the TGF-β superfamily and FSLT1 is an inhibitor of activin A [19]. Kusama et al reported that FLST1 increased on day 20 uterine flushing and decreased on
day 22, whereas they found an elevated activin A on day 20 and further increased on day 22. [21].

Kusama et al reported Activin A-induced EMT marker expressions were inhibited by FLST in the embryonic trophectoderm cells CT-1 [21]. To analyze the interaction between activin A and FLST1 in bovine trophoblasts with epithelial or mesenchymal phenotype, BBT-9 or BBT-18 cells were treated with Activin A or Activin A + FLST1.

As a readout we decided to focus on the possible variations in the secretion pattern of a selected group of proteins related to the process of invasive growth and thus potentially involved in the regulation of embryo implantation: TDFG1, HSPH1, MMP2, and PEG3 [11, 14, 27, 46]. Our embryonic trophectoderm primary cultures either with epithelial or mesenchymal phenotype, responded to Activin A or Activin + FLST1 stimulations by secreting the implantation proteins in EVs-cargo. Mitko et al. reported a marked increase in the expression of TDFG1 at day 12, connected with the process of invasive growth and regulating the embryo implantation [27]. Hatayama et al reported a marked increase in the expression of HSPH1 in mouse embryos between days 9 and 12, coinciding with organogenesis, and they attributed to HSPH1 a relevant function in organogenesis during embryonic development [15]. Later, Yuan et al also reported the presence of HSPH1 in rat embryos [45]. In our in vitro model of communication between maternal MSCs and embryonic trophectoderm through EVs, we observed a marked expression of HSPH1 in EVs from trophectoderm with the epithelial phenotype (BBT-18), that was further increased in the presence of Activin A. In contrast, the expression of HSPH1 in EVs from embryonic trophectoderm with mesenchymal phenotype was much lower. MMP2, a member of the matrix metallopeptidase family, which is involved in the breakdown of extracellular matrix in normal physiological processes, and PEG3 are up-regulated on Day 13 in vivo conceptuses [44].

In conclusion, we have confirmed different epithelial-mesenchymal transition stages in embryonic trophectoderm primary cultures. The embryonic trophoderm secretome contains early pregnancy-related proteins and angiogenic markers both as cargo in EVs and the soluble fraction. We have demonstrated the functional transfer of protein-containing secretome between embryonic trophectoderm and maternal MSC and its chemotaxis capacity, thus suggesting that this system could be used as an in vitro model of cell-to-cell communication through EVs and soluble proteins. In a complementary way, the pattern of secretion of implantation proteins in trophectoderm-EVs changes depending on: i) its epithelial or mesenchymal phenotype; ii) as a result of the uptake of eMSC- or pbMSC-EVs previously stimulated or not with embryonic signals; and iii) because of stimulation with endometrial cytokines present in the uterine fluid in the peri-implantation period.

Figure 7 shows a chronologic schematic representation of BBT identified proteins associated with the main reproductive or EMT events.

**Declarations**

**Acknowledgments**
The authors want to thank the electron microscopy unit, the proteomic unit especially to Anabel Marina, and the Optical and Confocal Microscopy Service (Lab. 310) of “Severo Ochoa” Molecular Biology Center (CSIC-UAM), and especially to Dr. Carmen Sánchez Jiménez.

*The proteomic analysis: “Protein Identification by LC-MS/MS” was carried out in the ‘CBMSO PROTEIN CHEMISTRY FACILITY’, which belongs to ProteoRed, PRB3-ISCIII, supported by grant PT17/0019”.*

**Funding**

This study was supported by grants from the Spanish Ministerio de Economía Industria y Competitividad to Ramírez M. A. (AGL2015-70140-R), Spanish Ministerio de Ciencia e Innovación to Ramírez M. A. (PID2019-107145RB-I00) and to Yáñez-Mo M. (BIO2017-86500-R), Spanish Ministerio para la Transición Ecológica y el Reto Demográfico, through Fundación Biodiversidad to Ramírez M. A. (PRCV00820) and European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 731014 (Ramírez M. A.).

**Conflict of Interest**

The authors declare that they have no conflict of interests.

**Ethics approval**

Not applicable

**Author contributions**

M. A. R.: conception and design, financial support; A. C. and M. A. R.: provision of study material, collection and assembly of data, data analysis and interpretation, manuscript writing, and final approval of the manuscript; V. T. S.: provision of study material and critical review of the manuscript; M. Y. M.: data analysis and interpretation, manuscript writing, and final approval of the manuscript.

**References**

1. Acloque, H., Adams, M. S., Fishwick, K., Bronner-Fraser, M., & Nieto, M. A. (2009). Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. *J Clin Invest, 119*(6), 1438-1449. https://doi.org/10.1172/JCI38019

2. Alonso, R., Pisa, D., Marina, A. I., Morato, E., Rábano, A., Rodal, I., & Carrasco, L. (2015). Evidence for fungal infection in cerebrospinal fluid and brain tissue from patients with amyotrophic lateral sclerosis. *Int J Biol Sci, 11*(5), 546-558. https://doi.org/10.7150/ijbs.11084

3. Bai, R., Bai, H., Kuse, M., Ideta, A., Aoyagi, Y., Fujiwara, H., Okuda, K., Imakawa, K., & Sakurai, T. (2014). Involvement of VCAM-1 in the bovine conceptus adhesion to the uterine endometrium. *Reproduction*. https://doi.org/10.1530/REP-13-0655
4. Bai, R., Kusama, K., Nakamura, K., Sakurai, T., Kimura, K., Ideta, A., Aoyagi, Y., & Imakawa, K. (2018). Down-regulation of transcription factor OVOL2 contributes to epithelial-mesenchymal transition in a noninvasive type of trophoblast implantation to the maternal endometrium. *FASEB J*, 32(6), 3371-3384. https://doi.org/10.1096/fj.201701131RR

5. Barreiro, O., Yanez-Mo, M., Serrador, J. M., Montoya, M. C., Vicente-Manzanares, M., Tejedor, R., Furtthmayr, H., & Sanchez-Madrid, F. (2002). Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. *J Cell Biol*, 157(7), 1233-1245. https://doi.org/10.1083/jcb.200112126

6. Billottet, C., Tuefferd, M., Gentien, D., Rapinat, A., Thiery, J. P., Broët, P., & Jouanneau, J. (2008). Modulation of several waves of gene expression during FGF-1 induced epithelial-mesenchymal transition of carcinoma cells. *J Cell Biochem*, 104(3), 826-839. https://doi.org/10.1002/jcb.21667

7. Calle, A., Barrajón-Masa, C., Gómez-Fidalgo, E., Martín-Lluch, M., Cruz-Vigo, P, Sánchez-Sánchez, R., & Ramírez, M. Á. (2018). Iberian pig mesenchymal stem/stromal cells from dermal skin, abdominal and subcutaneous adipose tissues, and peripheral blood: in vitro characterization and migratory properties in inflammation. *Stem Cell Res Ther*, 9(1), 178. https://doi.org/10.1186/s13287-018-0933-y

8. Calle, A., Gutiérrez-Reinoso, M. Á., Re, M., Blanco, J., De la Fuente, J., Monguí-Tortajada, M., Borràs, F. E., Yáñez-Mó, M., & Ramírez, M. Á. (2021). Bovine peripheral blood MSCs chemotax towards inflammation and embryo implantation stimuli. *J Cell Physiol*, 236(2), 1054-1067. https://doi.org/10.1002/jcp.29915

9. Calle, A., López-Martín, S., Monguí-Tortajada, M., Borràs, F. E., Yáñez-Mó, M., & Ramírez, M. Á. (2019). Bovine endometrial MSC: mesenchymal to epithelial transition during luteolysis and tropism to implantation niche for immunomodulation. *Stem Cell Res Ther*, 10(1), 239. https://doi.org/10.1186/s13287-018-1129-1

10. Caltabiano, S., Hum, W. T., Attwell, G. J., Gralnick, D. N., Budman, L. J., Cannistraci, A. M., & Bex, F. J. (1999). The integrin specificity of human recombinant osteopontin. *Biochem Pharmacol*, 58(10), 1567-1578. https://doi.org/10.1016/s0006-2952(99)00251-8

11. Clemente, M., Lopez-Vidriero, I., O’Gaora, P, Mehta, J. P., Forde, N., Gutierrez-Adan, A., Lonergan, P, & Rizos, D. (2011). Transcriptome changes at the initiation of elongation in the bovine conceptus. *Biol Reprod*, 85(2), 285-295. https://doi.org/10.1095/biolreprod.111.091587

12. Colnot, C., Fowlis, D., Ripoche, M. A., Bouchaert, I., & Poirier, F. (1998). Embryonic implantation in galectin 1/galectin 3 double mutant mice. *Dev Dyn*, 211(4), 306-313. https://doi.org/10.1002/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L

13. Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P, Grisanti, S., & Gianni, A. M. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood*, 99(10), 3838-3843. https://doi.org/10.1182/blood.v99.10.3838
14. Fang, Z. F., Gai, H., Huang, Y. Z., Li, S. G., Chen, X. J., Shi, J. J., Wu, L., Liu, A., Xu, P., & Sheng, H. Z. (2006). Rabbit embryonic stem cell lines derived from fertilized, parthenogenetic or somatic cell nuclear transfer embryos. *Exp Cell Res, 312*(18), 3669-3682. https://doi.org/10.1016/j.yexcr.2006.08.013

15. Hatayama, T., Takigawa, T., Takeuchi, S., & Shiota, K. (1997). Characteristic expression of high molecular mass heat shock protein HSP105 during mouse embryo development. *Cell Struct Funct, 22*(5), 517-525. https://doi.org/10.1247/csf.22.517

16. Hayashi, K. G., Hosoe, M., Fujii, S., Kanahara, H., & Sakamoto, R. (2019). Temporal expression and localization of vascular endothelial growth factor family members in the bovine uterus during peri-implantation period. *Theriogenology, 133*, 56-64. https://doi.org/10.1016/j.theriogenology.2019.04.021

17. Hoffert-Goeres, K. A., Batchelder, C. A., Bertolini, M., Moyer, A. L., Famula, T. R., & Anderson, G. B. (2007). Angiogenesis in day-30 bovine pregnancies derived from nuclear transfer. *Cloning Stem Cells, 9*(4), 595-607. https://doi.org/10.1089/clo.2007.0019

18. Imakawa, K., Bai, R., Fujiwara, H., Ideta, A., Aoyagi, Y., & Kusama, K. (2017). Continuous model of conceptus implantation to the maternal endometrium. *J Endocrinol, 233*(1), R53-R65. https://doi.org/10.1530/JOE-16-0490

19. Jones, R. L., Salamonsen, L. A., & Findlay, J. K. (2002). Potential roles for endometrial inhibins, activins and follistatin during human embryo implantation and early pregnancy. *Trends Endocrinol Metab, 13*(4), 144-150. https://doi.org/10.1016/s1043-2760(01)00559-8

20. Kotrbová, A., Štěpka, K., Maška, M., Páleník, J. J., Ilkovics, L., Klemová, D., Kravec, M., Hubatka, F., Dave, Z., Hampl, A., Bryja, V., Matula, P., & Pospíchalová, V. (2019). TEM ExosomeAnalyzer: a computer-assisted software tool for quantitative evaluation of extracellular vesicles in transmission electron microscopy images. *J Extracell Vesicles, 8*(1), 1560808. https://doi.org/10.1080/20013078.2018.1560808

21. Kusama, K., Bai, R., Ideta, A., Aoyagi, Y., Okuda, K., & Imakawa, K. (2016). Regulation of epithelial to mesenchymal transition in bovine conceptuses through the interaction between follistatin and activin A. *Mol Cell Endocrinol, 434*, 81-92. https://doi.org/10.1016/j.mce.2016.06.017

22. Lee, B., Villarreal-Ponce, A., Fallahi, M., Ovadia, J., Sun, P., Yu, Q. C., Ito, S., Sinha, S., Nie, Q., & Dai, X. (2014). Transcriptional mechanisms link epithelial plasticity to adhesion and differentiation of epidermal progenitor cells. *Dev Cell, 29*(1), 47-58. https://doi.org/10.1016/j.devcel.2014.03.005

23. Liu, L., Zhao, G., Fan, H., Zhao, X., Li, P., Wang, Z., Hu, Y., & Hou, Y. (2014). Mesenchymal stem cells ameliorate Th1-induced pre-eclampsia-like symptoms in mice via the suppression of TNF-α expression. *PLoS One, 9*(2), e88036. https://doi.org/10.1371/journal.pone.0088036

24. Lopera-Vásquez, R., Hamdi, M., Fernandez-Fueres, B., Maillo, V., Beltrán-Breña, P., Calle, A., Redruello, A., López-Martín, S., Gutierrez-Adán, A., Yañez-Mó, M., Ramirez, M. Á., & Rizos, D. (2016). Extracellular Vesicles from BOEC in In Vitro Embryo Development and Quality. *PLoS One, 11*(2), e0148083. https://doi.org/10.1371/journal.pone.0148083
25. Mendez-Huergo, S. P., Hockl, P. F., Stupirski, J. C., Maller, S. M., Morosi, L. G., Pinto, N. A., Berón, A. M., Musuruana, J. L., Nasswetter, G. G., Cavallasca, J. A., & Rabinovich, G. A. (2018). Clinical Relevance of Galectin-1 and Galectin-3 in Rheumatoid Arthritis Patients: Differential Regulation and Correlation With Disease Activity. *Front Immunol, 9*, 3057. https://doi.org/10.3389/fimmu.2018.03057

26. Meng, Y. H., Zhu, X. H., Yan, L. Y., Zhang, Y., Jin, H. Y., Xia, X., Li, R., & Qiao, J. (2016). Bone mesenchymal stem cells improve pregnancy outcome by inducing maternal tolerance to the allogeneic fetus in abortion-prone matings in mouse. *Placenta, 47*, 29-36. https://doi.org/10.1016/j.placenta.2016.08.089

27. Mitko, K., Ulbrich, S. E., Wenigerkind, H., Sinowatz, F., Blum, H., Wolf, E., & Bauersachs, S. (2008). Dynamic changes in messenger RNA profiles of bovine endometrium during the oestrous cycle. *Reproduction, 135*(2), 225-240. https://doi.org/10.1530/REP-07-0415

28. Nakano, H., Shimada, A., Imai, K., Takahashi, T., & Hashizume, K. (2005). The cytoplasmic expression of E-cadherin and beta-catenin in bovine trophoblasts during binucleate cell differentiation. *Placenta, 26*(5), 393-401. https://doi.org/10.1016/j.placenta.2004.08.002

29. Pang, M. F., Georgoudaki, A. M., Lambut, L., Johansson, J., Tabor, V., Hagikura, K., Jin, Y., Jansson, M., Alexander, J. S., Nelson, C. M., Jakobsson, L., Betsholtz, C., Sund, M., Karlsson, M. C., & Fuxe, J. (2016). TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis. *Oncogene, 35*(6), 748-760. https://doi.org/10.1038/onc.2015.133

30. Pfarrer, C., Hirsch, P., Guillomot, M., & Leiser, R. (2003). Interaction of integrin receptors with extracellular matrix is involved in trophoblast giant cell migration in bovine placentomes. *Placenta, 24*(6), 588-597. https://doi.org/10.1016/s0143-4004(03)00059-6

31. Pfarrer, C. D. (2006). Characterization of the bovine placenta by cytoskeleton, integrin receptors, and extracellular matrix. *Methods Mol Med, 121*, 323-335. https://doi.org/10.1385/1-59259-983-4:321

32. Ramos-Ibeas, P., Calle, A., Pericuesta, E., Laguna-Barraza, R., Moros-Mora, R., Lopera-Vasquez, R., Maillo, V., Yanez-Mo, M., Gutierrez-Adan, A., Rizos, D., & Ramirez, M. A. (2014). An Efficient System to Establish Biopsy-Derived Trophoblastic Cell Lines from Bovine Embryos. *Biology of Reproduction*. https://doi.org/10.1095/biolreprod.114.118430

33. Ranieri, D., Rosato, B., Nanni, M., Magenta, A., Belleudi, F., & Torrisi, M. R. (2016). Expression of the FGFR2 mesenchymal splicing variant in epithelial cells drives epithelial-mesenchymal transition. *Oncotarget, 7*(5), 5440-5460. https://doi.org/10.18632/oncotarget.6706

34. Schnapp, L. M., Hatch, N., Ramos, D. M., Klimanskaya, I. V., Sheppard, D., & Pytela, R. (1995). The human integrin alpha 8 beta 1 functions as a receptor for tenascin, fibronectin, and vitronectin. *J Biol Chem, 270*(39), 23196-23202. https://doi.org/10.1074/jbc.270.39.23196

35. Škovierová, H., Okajčková, T., Strnádel, J., Vidomanová, E., & Halašová, E. (2018). Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review). *Int J Mol Med, 41*(3), 1187-1200. https://doi.org/10.3892/ijmm.2017.3320
36. Suárez, H., Gámez-Valero, A., Reyes, R., López-Martín, S., Rodríguez, M. J., Carrascosa, J. L., Cabañas, C., Borràs, F. E., & Yáñez-Mó, M. (2017). A bead-assisted flow cytometry method for the semi-quantitative analysis of Extracellular Vesicles. Sci Rep, 7(1), 11271. https://doi.org/10.1038/s41598-017-11249-2

37. Talbot, N. C., Caperna, T. J., Edwards, J. L., Garrett, W., Wells, K. D., & Ealy, A. D. (2000). Bovine blastocyst-derived trophectoderm and endoderm cell cultures: interferon tau and transferrin expression as respective in vitro markers. Biol Reprod, 62(2), 235-247. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10642558

38. Talbot, N. C., Caperna, T. J., Powell, A. M., Garrett, W. M., & Ealy, A. D. (2004). Isolation and characterization of a bovine trophectoderm cell line derived from a parthenogenetic blastocyst. Mol Reprod Dev, 69(2), 164-173. https://doi.org/10.1002/mrd.20165

39. Talbot, N., Powell, A., Camp, M., & Ealy, A. (2007). Establishment of a bovine blastocyst-derived cell line collection for the comparative analysis of embryos created in vivo and by in vitro fertilization, somatic cell nuclear transfer, or parthenogenetic activation. In Vitro Cellular & Developmental Biology - Animal, 43(2), 59-71. https://doi.org/10.1007/s11626-007-9013-9

40. Tran, N. H., Qiao, R., Xin, L., Chen, X., Liu, C., Zhang, X., Shan, B., Ghodsi, A., & Li, M. (2019). Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry. Nat Methods, 16(1), 63-66. https://doi.org/10.1038/s41592-018-0260-3

41. Tran, N. H., Rahman, M. Z., He, L., Xin, L., Shan, B., & Li, M. (2016). Complete De Novo Assembly of Monoclonal Antibody Sequences. Sci Rep, 6, 31730. https://doi.org/10.1038/srep31730

42. Tran, N. H., Zhang, X., Xin, L., Shan, B., & Li, M. (2017). De novo peptide sequencing by deep learning. Proc Natl Acad Sci USA, 114(31), 8247-8252. https://doi.org/10.1073/pnas.1705691114

43. Vacca, P., Montaldo, E., Vitale, C., Croxatto, D., Moretta, L., & Mingari, M. C. (2015). MSC and innate immune cell interactions: A lesson from human decidua. Immunol Lett, 168(2), 170-174. https://doi.org/10.1016/j.imlet.2015.05.006

44. Yamakoshi, S., Bai, R., Chaen, T., Ideta, A., Aoyagi, Y., Sakurai, T., Konno, T., & Imakawa, K. (2012). Expression of mesenchymal-related genes by the bovine trophectoderm following conceptus attachment to the endometrial epithelium. Reproduction, 143(3), 377-387. https://doi.org/10.1530/REP-11-0364

45. Yuan, J. X., Xiao, L. J., Lu, C. L., Zhang, X. S., Liu, T., Chen, M., Hu, Z. Y., Gao, F., & Liu, Y. X. (2009). Increased expression of heat shock protein 105 in rat uterus of early pregnancy and its significance in embryo implantation. Reprod Biol Endocrinol, 7, 23. https://doi.org/10.1186/1477-7827-7-23

46. Zhou, W., Xiang, T., Walker, S., Abruzzese, R. V., Hwang, E., Farrar, V., Findeisen, B., Sadeghieh, S., Arenivas, F., Chen, S. H., & Polejaeva, I. (2008). Aggregation of bovine cloned embryos at the four-cell stage stimulated gene expression and in vitro embryo development. Mol Reprod Dev, 75(8), 1281-1289. https://doi.org/10.1002/mrd.20875
47. Zou, Y., Gong, P., Zhao, W., Zhang, J., Wu, X., Xin, C., Xiong, Z., Li, Z., Wu, X., Wan, Q., Li, X., & Chen, J. (2019). Quantitative iTRAQ-based proteomic analysis of piperine protected cerebral ischemia/reperfusion injury in rat brain. *Neurochem Int, 124*, 51-61.
https://doi.org/10.1016/j.neuint.2018.12.010